Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: ITGB1BP1

Gene summary for ITGB1BP1

Gene summary.

Gene information	Species	Human
	Gene symbol	ITGB1BP1
	Gene ID	9270
	Gene name	integrin subunit beta 1 binding protein 1
	Gene Alias	ICAP-1A
	Cytomap	2p25.1
	Gene Type	protein-coding
	GO ID	GO:0000165
	UniProtAcc	O14713

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
9270	ITGB1BP1	LZE4T	Human	Esophagus	ESCC	3.19e-22	7.32e-01	0.0811
9270	ITGB1BP1	LZE5T	Human	Esophagus	ESCC	9.94e-04	2.39e-01	0.0514
9270	ITGB1BP1	LZE7T	Human	Esophagus	ESCC	1.76e-07	6.14e-01	0.0667
9270	ITGB1BP1	LZE20T	Human	Esophagus	ESCC	1.83e-03	2.09e-01	0.0662
9270	ITGB1BP1	LZE22T	Human	Esophagus	ESCC	4.25e-04	9.11e-01	0.068
9270	ITGB1BP1	LZE24T	Human	Esophagus	ESCC	3.49e-19	7.05e-01	0.0596
9270	ITGB1BP1	LZE21T	Human	Esophagus	ESCC	2.61e-04	4.43e-01	0.0655
9270	ITGB1BP1	LZE6T	Human	Esophagus	ESCC	5.81e-10	6.17e-01	0.0845
9270	ITGB1BP1	P1T-E	Human	Esophagus	ESCC	1.52e-09	5.19e-01	0.0875
9270	ITGB1BP1	P2T-E	Human	Esophagus	ESCC	1.05e-32	7.46e-01	0.1177
9270	ITGB1BP1	P4T-E	Human	Esophagus	ESCC	5.40e-38	9.82e-01	0.1323
9270	ITGB1BP1	P5T-E	Human	Esophagus	ESCC	3.34e-48	9.79e-01	0.1327
9270	ITGB1BP1	P8T-E	Human	Esophagus	ESCC	7.49e-31	5.27e-01	0.0889
9270	ITGB1BP1	P9T-E	Human	Esophagus	ESCC	3.25e-28	6.81e-01	0.1131
9270	ITGB1BP1	P10T-E	Human	Esophagus	ESCC	1.51e-57	1.10e+00	0.116
9270	ITGB1BP1	P11T-E	Human	Esophagus	ESCC	6.14e-24	1.15e+00	0.1426
9270	ITGB1BP1	P12T-E	Human	Esophagus	ESCC	4.50e-40	7.29e-01	0.1122
9270	ITGB1BP1	P15T-E	Human	Esophagus	ESCC	7.10e-35	9.40e-01	0.1149
9270	ITGB1BP1	P16T-E	Human	Esophagus	ESCC	9.15e-20	3.67e-01	0.1153
9270	ITGB1BP1	P17T-E	Human	Esophagus	ESCC	1.15e-11	9.66e-01	0.1278

Page: 1 2 3 4 5 6 7

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:004578520	Oral cavity	OSCC	positive regulation of cell adhesion	225/7305	437/18723	6.06e-08	1.09e-06	225
GO:003295620	Oral cavity	OSCC	regulation of actin cytoskeleton organization	189/7305	358/18723	6.81e-08	1.21e-06	189
GO:004340917	Oral cavity	OSCC	negative regulation of MAPK cascade	105/7305	180/18723	1.10e-07	1.87e-06	105
GO:011005320	Oral cavity	OSCC	regulation of actin filament organization	150/7305	278/18723	2.68e-07	4.15e-06	150
GO:000195215	Oral cavity	OSCC	regulation of cell-matrix adhesion	78/7305	128/18723	4.05e-07	6.02e-06	78
GO:002260419	Oral cavity	OSCC	regulation of cell morphogenesis	163/7305	309/18723	5.66e-07	8.19e-06	163
GO:190547716	Oral cavity	OSCC	positive regulation of protein localization to membrane	65/7305	106/18723	2.69e-06	3.32e-05	65
GO:000716016	Oral cavity	OSCC	cell-matrix adhesion	125/7305	233/18723	3.76e-06	4.45e-05	125
GO:004586016	Oral cavity	OSCC	positive regulation of protein kinase activity	194/7305	386/18723	3.90e-06	4.59e-05	194
GO:003367418	Oral cavity	OSCC	positive regulation of kinase activity	228/7305	467/18723	8.31e-06	8.90e-05	228
GO:19035337	Oral cavity	OSCC	regulation of protein targeting	51/7305	81/18723	1.08e-05	1.13e-04	51
GO:00107618	Oral cavity	OSCC	fibroblast migration	33/7305	47/18723	1.43e-05	1.44e-04	33
GO:005189316	Oral cavity	OSCC	regulation of focal adhesion assembly	43/7305	66/18723	1.52e-05	1.52e-04	43
GO:009010916	Oral cavity	OSCC	regulation of cell-substrate junction assembly	43/7305	66/18723	1.52e-05	1.52e-04	43
GO:00336274	Oral cavity	OSCC	cell adhesion mediated by integrin	46/7305	72/18723	1.66e-05	1.64e-04	46
GO:00066123	Oral cavity	OSCC	protein targeting to membrane	75/7305	131/18723	1.72e-05	1.69e-04	75
GO:00320919	Oral cavity	OSCC	negative regulation of protein binding	57/7305	94/18723	1.75e-05	1.71e-04	57
GO:001081120	Oral cavity	OSCC	positive regulation of cell-substrate adhesion	71/7305	123/18723	1.96e-05	1.87e-04	71
GO:015011617	Oral cavity	OSCC	regulation of cell-substrate junction organization	45/7305	71/18723	2.76e-05	2.56e-04	45
GO:005067310	Oral cavity	OSCC	epithelial cell proliferation	212/7305	437/18723	2.82e-05	2.61e-04	212

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

ITGB1BP1

SNV

Missense_Mutation

c.592N>A

p.Glu198Lys

p.E198K

O14713

protein_coding

tolerated(0.25)

benign(0.185)

TCGA-D8-A1XQ-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

ITGB1BP1

SNV

Missense_Mutation

c.83N>G

p.Ser28Cys

p.S28C

O14713

protein_coding

tolerated(0.12)

probably_damaging(0.996)

TCGA-JW-A5VL-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

ITGB1BP1

SNV

Missense_Mutation

rs773209764

c.8G>A

p.Arg3His

p.R3H

O14713

protein_coding

deleterious_low_confidence(0.01)

probably_damaging(0.991)

TCGA-AA-A00N-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Unknown

ITGB1BP1

SNV

Missense_Mutation

c.83N>A

p.Ser28Tyr

p.S28Y

O14713

protein_coding

deleterious(0.03)

probably_damaging(0.995)

TCGA-A5-A0G2-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Unknown

ITGB1BP1

SNV

Missense_Mutation

rs376533619

c.317C>T

p.Pro106Leu

p.P106L

O14713

protein_coding

tolerated(0.31)

benign(0.007)

TCGA-AP-A059-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

ITGB1BP1

SNV

Missense_Mutation

novel

c.29N>A

p.Ser10Asn

p.S10N

O14713

protein_coding

tolerated_low_confidence(0.19)

probably_damaging(0.95)

TCGA-AP-A0LM-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

cisplatin

ITGB1BP1

SNV

Missense_Mutation

novel

c.122G>A

p.Ser41Asn

p.S41N

O14713

protein_coding

deleterious(0.03)

probably_damaging(0.988)

TCGA-B5-A1MX-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Hormone Therapy

megace

ITGB1BP1

SNV

Missense_Mutation

novel

c.526N>G

p.Ser176Gly

p.S176G

O14713

protein_coding

tolerated(0.13)

possibly_damaging(0.59)

TCGA-BK-A6W3-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

ITGB1BP1

SNV

Missense_Mutation

novel

c.439G>A

p.Gly147Ser

p.G147S

O14713

protein_coding

tolerated(0.27)

probably_damaging(0.999)

TCGA-EO-A22R-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

ITGB1BP1

SNV

Missense_Mutation

rs771640299

c.568N>A

p.Ala190Thr

p.A190T

O14713

protein_coding

tolerated(0.21)

benign(0.207)

TCGA-EO-A22U-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

Page: 1 2

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1